Republic of the Philippines
PHILIPPINE HEALTH INSURANCE CORPORATION
Citystate Centre, 709 Shaw Boulevard, Pasig City
(02) 8662-2588 www.philhealth.gov.ph
PhilHealthOfficial teamphilhealth

PHILHEALTH CIRCULAR
No. 2026 - 0018

TO : **ALL DRUG DISPENSING FACILITIES, HEALTHCARE INSTITUTIONS/PROVIDERS, AND ALL OTHERS CONCERNED**

SUBJECT : **Guidelines on Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth Guaranteed and Accessible Medications for Outpatient Treatment (PhilHealth GAMOT)**

I. RATIONALE

Pursuant to Republic Act No. 11223 (Universal Health Care Act), Republic Act No. 10767 (Comprehensive Tuberculosis Elimination Plan Act), and PhilHealth Board Resolution No. 3161 s. 2026, the Philippine Health Insurance Corporation (PhilHealth) hereby integrates the pharmaceutical component of Drug-Susceptible Tuberculosis (DS-TB) management into the PhilHealth Guaranteed and Accessible Medications for Outpatient Treatment (GAMOT) Program.

While the Outpatient Anti-Tuberculosis Directly Observed Treatment Short-Course (TB-DOTS) Package under PhilHealth Circular No. 2014-0014 remains the primary mechanism for comprehensive TB care, this Circular establishes a supplemental mechanism enabling accredited Primary Care Clinics (PC Clinics) and accredited Primary Care Physicians to prescribe first-line anti-TB drugs for dispensing through accredited GAMOT Facilities, facilitating increased access to quality-assured medications at the point of care.

II. OBJECTIVES

MASTER COPY Date: 10/13/26 DC:

This Circular aims to outline guidelines for PhilHealth accredited PC Clinics, TB-DOTS Facilities, and GAMOT Facilities.

A. Expand the current GAMOT List with first-line anti-TB drugs for drug-susceptible tuberculosis (DS-TB).

B. Ensure continuous and increased access to anti-TB medications by leveraging accredited GAMOT Facilities for drug dispensing.

C. Define the payment adjustments and reimbursement mechanism for both TB-DOTS Facilities and GAMOT Facilities.

III. SCOPE

This Circular encompasses the rules governing access to outpatient first-line anti-TB drugs for eligible PhilHealth members and dependents diagnosed with DS-TB through the PhilHealth GAMOT Program.

IV. DEFINITION OF TERMS

For the purpose of this Circular, the operational definitions of terms used in this issuance are the following:

A. **Authorized Physician** - accredited physician with a PhilHealth GAMOT Application account.

B. **Continuation Phase** - the second phase of tuberculosis treatment focused on eliminating residual bacilli, typically lasting 2 to 10 months using a reduced combination of anti-TB drugs.

C. **First-line anti-TB drugs** – a standard fixed-dose combination (FDC) or single-drug formulation used for the primary treatment of drug-susceptible tuberculosis as defined in the Department of Health National TB Control Program (NTP) Manual of Procedures (MOP) 6th edition.

D. **GAMOT Application (GAMOT App)** - a software that can be interoperable with existing operating systems, used to prescribe medications, validate prescriptions, record dispensing, and monitor performance of GAMOT Facilities, as applicable.

E. **GAMOT Facility** - a drug dispensing facility that is engaged by PhilHealth to provide the contents of the outpatient drug benefit package.

F. **Intensive Phase** - the initial phase of tuberculosis treatment aimed at rapidly killing active bacilli, typically lasting 2 months using a four-drug combination regimen.

G. **Outpatient Anti-Tuberculosis Directly Observed Treatment Short-Course Package (Outpatient TB-DOTS Package)** - a comprehensive outpatient benefit package rendered by accredited TB-DOTS facilities for TB cases diagnosed that are sensitive to first line anti-TB drugs, covering diagnostic exams, consultation services, drugs, health education and counseling during TB DOTS treatment following the National TB Control Program (NTP) guidelines.

MASTER COPY
DC: Date: 10/13/26

H. PhilHealth GAMOT - PhilHealth's outpatient drug benefit package which covers select medications used in the outpatient management and shall function as the pharmaceutical service delivery arm of PhilHealth's outpatient benefits. It shall be referred to as PhilHealth Guaranteed and Accessible Medications for Outpatient Treatment or PhilHealth GAMOT.

I. TB-DOTS Facility – a health facility accredited by PhilHealth to provide directly observed treatment short-course (DOTS) services for tuberculosis patients.

V. POLICY STATEMENTS

A. General Guidelines

1. This Circular shall serve as a supportive measure to promote treatment initiation and prevent treatment interruption for members and dependents diagnosed with DS-TB of first-line anti-TB drugs by incorporating these medications into PhilHealth GAMOT.

2. Accredited TB-DOTS Facilities with adequate and sustainable supplies of first-line anti-TB drugs shall continue providing comprehensive care—including directly dispensing anti-TB medications—and filing their full claims under the standard Outpatient TB-DOTS Package.

3. PhilHealth Circular (PC) No. 2014-0014 (Revised Guidelines for the PhilHealth Outpatient Anti-Tuberculosis Directly Observed Treatment Short-Course [DOTS] Benefit Package) remains the primary policy guidelines for the overall conduct, accreditation, and filing of claims under the Outpatient TB-DOTS Package.

4. PhilHealth Circular Nos. 2025-0013 (Nationwide Implementation of PhilHealth Guaranteed and Accessible Medications for Outpatient Treatment), 2026-0002 (Supplemental Guidelines for the Nationwide Implementation of PhilHealth Guaranteed and Accessible Medications for Outpatient Treatment [GAMOT]), and 2026-0007 (Clinical and Pharmaceutical Standards for PhilHealth Yaman ng Kalusugan Program [YAKAP]) remains the governing policies for the general conduct, accreditation, quality standards, and filing of claims under the PhilHealth GAMOT Program.

5. PhilHealth GAMOT shall cover select first-line anti-TB drugs for outpatient management of confirmed drug-susceptible tuberculosis (DS-TB) patients.

   a. The updated GAMOT List shall include the select first-line anti-TB drugs (Annex A.1: GAMOT List).

   b. Each first-line anti-TB drug included in the GAMOT List shall correspond to a fixed fee (Annex A.2: GAMOT Fixed Fee Schedule).

MASTER COPY
Date: 10/13/26
DC:

6. Only medications prescribed by authorized physicians through the GAMOT App shall be covered by this benefit.

7. All clinical management, prescribing, and dispensing protocols shall strictly adhere to the standards mandated by the Department of Health – National TB Control Program (DOH-NTP).

8. All accredited GAMOT Facilities shall update and submit an updated Certification of Availability of GAMOT signed by the Head of the Facility (Annex B: Certification of Availability of GAMOT Template) to their respective PROs prior to dispensing first-line anti-TB drugs under this policy.

B. Specific Guidelines

1. Prescribing of first-line anti-TB drugs by Authorized Physicians

a. Authorized physicians shall be able to prescribe select first-line anti-TB drugs for outpatient management of confirmed DS-TB patients through the GAMOT Application (GAMOT App).

b. Authorized physicians shall align the prescriptions with the patient's needs, clinical condition, and the first-line anti-TB drugs' approved therapeutic indications:

Table 1. Medications for DS-TB and Indications

Drug	Indications
Isoniazid + Rifampicin + Pyrazinamide + Ethambutol	Treatment of tuberculosis
Isoniazid + Rifampicin	Treatment of tuberculosis
Isoniazid + Rifampicin + Pyrazinamide	Treatment of tuberculosis
Ethambutol	Treatment of tuberculosis in combination with isoniazid, rifampicin, and pyrazinamide

Source: Electronic Philippine National Formulary (ePNF) accessed through https://pndf.doh.gov.ph/ last September 2, 2026

MASTER COPY
DC: Date: 10/13/26

c. The maximum dosing and treatment duration for first-line anti-TB drugs for outpatient management of confirmed DS-TB adults and children shall follow the guidelines of the DOH-NTP Manual of Procedures 6th Edition and its subsequent revisions.

c.1. To ensure close clinical monitoring and adherence, a maximum of one (1) month's worth of first-line anti-TB drugs may be prescribed per transaction.

c.2. To ensure uninterrupted care, refill prescriptions for first-line anti-TB medications may be issued and dispensed beginning 14 days after the previous prescription date.

2. Dispensing of First-Line Anti-TB Drugs by GAMOT Facilities

   a. The GAMOT Facility shall dispense in full the prescribed first-line anti-TB drugs within two (2) days from the date of GAMOT prescription issuance. Beyond the claiming period, the medications can still be dispensed by the pharmacy but paid out of pocket. The GAMOT prescription shall be updated by the authorized physician if the medications remain medically necessary.

   b. A maximum of one month's worth of medications shall be dispensed (Annex C: PhilHealth GAMOT First-Line Anti-TB Drugs Dispensing Limits).

3. Payment Mechanism

   a. First-line anti-TB drugs dispensed under PhilHealth GAMOT shall not be deductible from the member's Annual Benefit Limit (ABL).

   b. Accredited GAMOT Facilities shall be reimbursed directly by PhilHealth based on the fixed fee set for first-line anti-TB drugs (Annex A.2: GAMOT Fixed Fee Schedule).

4. Adjustment of TB-DOTS Package Claims

   a. A corresponding 50% deduction shall apply to the TB-DOTS package claims per treatment phase filed by the TB-DOTS Facility when first-line anti-TB drugs are dispensed through a GAMOT Facility instead of the TB-DOTS Facility.

   b. The deduction process shall be automatically triggered by the PhilHealth claims processing system upon detection and verification of a completed dispensing transaction for first-line anti-TB drugs under the GAMOT App for the specified member and treatment phase. Manual intervention by the facility to calculate deductions is not required.

MASTER COPY
DC: Date: 10/13/26

c. The applicable claim rate adjustments are summarized below:

Treatment Phase	Package Code	Case Rate	Adjusted Facility Claim
Intensive Phase	89221	Php 4,875.00	Php 2,437.50
Continuous Phase	89222	Php 2,925.00	Php 1,462.50

d. The provision of the complete set of required anti-TB medications for each treatment phase (Intensive Phase or Continuation Phase) shall strictly be sourced from a single provider entity. For any given phase, the full set of required drugs shall be provided entirely by either the TB-DOTS Facility or through an accredited GAMOT Facility.

d.1. Split or partial drug sourcing within the same treatment phase—where a portion of the medications is provided by the TB-DOTS facility and another portion by a GAMOT facility—is strictly prohibited.

d.2. The TB-DOTS facility shall be eligible to claim the full benefit amount corresponding to a treatment phase only if it directly provides the complete regimen of first-line anti-TB drugs required for that entire phase.

d.3. If the required first-line anti-TB drugs for a specific phase are provided through a GAMOT facility, the corresponding medicine component of the claim shall be governed by the applicable GAMOT dispensing and reimbursement guidelines.

C. List of Annexes

Annex A.1: GAMOT List
Annex A.2: GAMOT Fixed Fee Schedule
Annex B: Certification of Availability of GAMOT Template
Annex C: PhilHealth GAMOT First-Line Anti-TB Drugs Dispensing Limits

VI. PENALTY CLAUSE

Any violation of this Circular, terms and conditions of the Performance Commitment, and all existing related PhilHealth issuances shall be dealt with and penalized following the pertinent provision of RA 7875, as amended by RA 9241 and RA 10606 [National Health Insurance Act of 2013] and RA 11223 [Universal Health Care Act], and their respective Implementing Rules and Regulations.

MASTER COPY
DC: Date: 10/13/26

VII. SEPARABILITY CLAUSE

If any provision of this Circular shall be declared invalid, unconstitutional, or unenforceable, the validity of the remaining provisions shall not in any way be affected and shall remain enforceable.

VIII. REPEALING CLAUSE

Section V.A.3.c. Medications covered by other outpatient benefits of PhilHealth Circular No. 2025-0013 is hereby amended to exempt the Outpatient TB-DOTS Package, thereby permitting the prescription and dispensing of first-line anti-TB drugs under PhilHealth GAMOT as provided herein.

IX. DATE OF EFFECTIVITY

This Circular shall be published in any newspaper of general circulation and shall take effect fifteen (15) days after its publication. Further, this Circular shall be subsequently deposited with the Office of the National Administrative Register (ONAR) at the University of the Philippines Law Center.

BEVERLY LORRAINE C. HO, MD, MPH
Acting President and Chief Executive Officer

Date: 10/08/2026



GAMOT LIST

Anti-infectives

1. Albendazole
2. Amoxicillin[a]
3. Azithromycin
4. Cefixime
5. Cefuroxime
6. Ciprofloxacin[a]
7. Clarithromycin[a]
8. Clindamycin
9. Clotrimazole
10. Cloxacillin
11. Co-amoxiclav[a]
12. Co-trimoxazole (Sulfamethoxazole + Trimethoprim)[a]
13. Doxycycline
14. Erythromycin
15. Fluconazole
16. Ketoconazole
17. Mebendazole
18. Metronidazole
19. Nitrofurantoin[a]
20. Oseltamivir
21. Tobramycin
22. Tobramycin + Dexamethasone

Anti-thrombotics

23. Clopidogrel
24. Aspirin[a]

Anti-asthma and COPD

25. Budesonide + Formoterol
26. Fluticasone + Salmeterol[a]
27. Ipratropium
28. Montelukast
29. Prednisone[a]
30. Salbutamol[a]
31. Ipratropium + Salbutamol
32. Tiotropium

Supportive/Other Therapy

33. Aluminum Hydroxide + Magnesium Hydroxide
34. Butamirate
35. Celecoxib
36. Cetirizine
37. Colchicine
38. Chlorphenamine[a]
39. Diphenhydramine
40. Ferrous Salt (Iron Preparations)
41. Folic acid + Iron Ferrous
42. Ibuprofen
43. Lagundi (Vitex Negundo)
44. Loratadine
45. Mefenamic Acid
46. Naproxen
47. Omeprazole
48. Oral Rehydration Salts[a]
49. Paracetamol[a]
50. Tamsulosin
51. Zinc

Anti-diabetics

52. Dapagliflozin
53. Gliclazide[a]
54. Metformin[a]

Anti-dyslipidemia

55. Atorvastatin
56. Fenofibrate
57. Rosuvastatin
58. Simvastatin[a]

Anti-hypertensive and Cardiology

59. Amlodipine[a]
60. Atenolol
61. Captopril
62. Clonidine
63. Diltiazem
64. Enalapril[a]
65. Enalapril + Hydrochlorothiazide
66. Hydrochlorothiazide[a]
67. Isosorbide Dinitrate
68. Isosorbide Mononitrate
69. Losartan[a]
70. Losartan + Hydrochlorothiazide
71. Methyldopa
72. Metoprolol[a]
73. Telmisartan
74. Telmisartan + Hydrochlorothiazide
75. Valsartan
76. Valsartan + Hydrochlorothiazide

Nervous System

77. Gabapentin

First-Line anti-TB

78. Ethambutol
79. Isoniazid + Rifampicin
80. Isoniazid + Rifampicin + Pyrazinamide
81. Isoniazid + Rifampicin + Pyrazinamide + Ethambutol

[a]21 drugs included in PhilHealth YAKAP (formerly Konsulta); covered under PhilHealth YAKAP for CY 2026

MASTER COPY
DC: Date: 10/9/26

No.	Molecule	Preparation	fixed fee
1	Albendazole	400 mg chewable tablet	₱9.75
2	Aluminum Hydroxide + Magnesium Hydroxide	200 mg + 100 mg tablet	₱8.50
3	Aluminum Hydroxide + Magnesium Hydroxide	225 mg + 200 mg/5 mL suspension in 60 mL	₱50.50
4	Aluminum Hydroxide + Magnesium Hydroxide	225 mg + 200 mg/5 mL suspension in 120 mL	₱104.00
5	Amlodipine[a]	5 mg (as besilate/camsylate) tablet	₱4.50
6	Amlodipine[a]	10 mg (as besilate/camsylate) tablet	₱6.50
7	Amoxicillin[a]	250 mg (as trihydrate) capsule	₱4.00
8	Amoxicillin[a]	500 mg (as trihydrate) capsule	₱5.25
9	Amoxicillin[a]	100 mg/mL (as trihydrate) granules/powder for drops in 15 mL	₱58.25
10	Amoxicillin[a]	250 mg/5 mL (as trihydrate) granules/powder for suspension in 60 mL	₱92.50
11	Amoxicillin + Clavulanic acid (Co-Amoxiclav)[a]	500 mg (as trihydrate) + 125 mg (as potassium clavulanate) tablet	₱25.75
12	Amoxicillin + Clavulanic acid (Co-Amoxiclav)[a]	875 mg (as trihydrate) + 125 mg (as potassium clavulanate) tablet	₱41.25
13	Amoxicillin + Clavulanic acid (Co-Amoxiclav)[a]	200 mg (as trihydrate) + 28.5 mg (as potassium clavulanate) per 5 mL granules/powder for suspension in 70 mL	₱244.50
14	Amoxicillin + Clavulanic acid (Co-Amoxiclav)[a]	400 mg (as Trihydrate) + 57 mg (as Potassium clavulanate) per 5 mL granules/powder for suspension in 70 mL	₱312.00
15	Amoxicillin + Clavulanic acid (Co-Amoxiclav)[a]	600 mg (as Trihydrate) + 42.9 mg (as Potassium clavulanate) per 5 mL granules/powder for suspension in 70 mL	₱230.00
16	Aspirin[a]	80 mg tablet	₱2.75
17	Aspirin[a]	100 mg tablet	₱1.75
18	Atenolol	50 mg tablet	₱5.50
19	Atenolol	100 mg tablet	₱11.75
20	Atorvastatin	10 mg (as calcium) tablet	₱10.00
21	Atorvastatin	20 mg (as calcium) tablet	₱12.25
22	Atorvastatin	40 mg (as calcium) tablet	₱17.25
23	Atorvastatin	80 mg (as calcium) tablet	₱25.00
24	Azithromycin	250 mg (as base/dihydrate) capsule	₱35.00
25	Azithromycin	250 mg (as base/dihydrate/ monohydrate) tablet	₱100.00
26	Azithromycin	500 mg (as base/dihydrate/ monohydrate) tablet	₱74.25
27	Azithromycin	200 mg/5 mL (as base/dihydrate/ monohydrate) powder for suspension in 15 mL	₱270.00
28	Azithromycin	200 mg/5 mL (as base/dihydrate/ monohydrate) powder for suspension in 60 mL	₱262.50
29	Budesonide + Formoterol	80 mcg + 4.5 mcg (as fumarate dihydrate) x 60 doses DPI with appropriate accompanying dispenser	₱853.25
30	Budesonide + Formoterol	160 mcg + 4.5 mcg (as fumarate dihydrate) x 60 doses DPI with appropriate accompanying dispenser	₱1,105.00
31	Budesonide + Formoterol	320 mcg + 9 mcg (as fumarate) x 60 doses DPI with appropriate accompanying dispenser	₱1,533.50
32	Budesonide + Formoterol	80 mcg + 4.5 mcg (as fumarate dihydrate) x 120 doses MDI with appropriate accompanying dispenser	₱590.50

MASTER COPY
DOH Date: 10/3/26

No.	Molecule	Preparation	fixed fee
33	Budesonide + Formoterol	160 mcg + 4.5 mcg (as fumarate dihydrate) x 120 doses MDI with appropriate accompanying dispenser	₱719.75
34	Butamirate	50 mg (as citrate) modified release tablet	₱8.50
35	Butamirate	7.5 mg/5 mL (as citrate) syrup in 120 mL	₱121.75
36	Captopril	25 mg tablet	₱5.25
37	Captopril	50 mg tablet	₱28.00
38	Cefixime	200 mg capsule	₱63.00
39	Cefixime	400 mg capsule	₱127.25
40	Cefixime	20 mg/mL granules for suspension (drops) in 10 mL	₱298.75
41	Cefixime	100 mg/5 mL granules for suspension in 60 mL	₱317.50
42	Cefuroxime	500 mg (as axetil) tablet	₱37.25
43	Cefuroxime	125 mg/5 mL (as axetil) granules for suspension in 70 mL	₱309.00
44	Cefuroxime	250 mg/5 mL granules for suspension in (50 mL content) in 120 mL Bottle	₱320.25
45	Celecoxib	100 mg capsule	₱31.00
46	Celecoxib	200 mg capsule	₱21.00
47	Celecoxib	400 mg capsule	₱39.50
48	Cetirizine	10 mg (as dihydrochloride) tablet	₱11.25
49	Cetirizine	2.5 mg/mL (as dihydrochloride) syrup (drops) in 10 mL	₱126.50
50	Cetirizine	10 mg/mL (as dihydrochloride) drops in 10 ml	₱110.25
51	Cetirizine	1 mg/mL (as dihydrochloride) solution in 30 mL	₱91.00
52	Cetirizine	1 mg/mL (as dihydrochloride) solution in 60 mL	₱119.50
53	Cetirizine	5 mg/5 mL (as dihydrochloride) syrup 30 mL	₱122.50
54	Chlorphenamine[a]	4 mg (as maleate) tablet	₱4.00
55	Chlorphenamine[a]	2.5 mg/5 mL (as maleate) syrup in 60 mL	₱37.75
56	Ciprofloxacin[a]	250 mg (as hydrochloride) tablet	₱32.00
57	Ciprofloxacin[a]	500 mg (as hydrochloride) tablet	₱25.00
58	Clarithromycin[a]	250 mg (as base) tablet	₱48.25
59	Clarithromycin[a]	500 mg (as base) tablet	₱56.00
60	Clarithromycin[a]	125 mg/5 mL granules/powder for suspension in 50 mL	₱277.00
61	Clarithromycin[a]	250 mg/5 mL granules/powder for suspension in 50 mL	₱632.50
62	Clindamycin	150 mg (as hydrochloride) capsule	₱14.75
63	Clindamycin	300 mg (as hydrochloride) capsule	₱29.75
64	Clindamycin	75 mg/5 mL (as palmitate hydrochloride) granules for suspension in 60 mL	₱568.75
65	Clonidine	75 mcg (as hydrochloride) tablet	₱16.50
66	Clonidine	150 mcg (as hydrochloride) tablet	₱21.50
67	Clopidogrel	75 mg tablet	₱20.25
68	Clotrimazole	1% Cream in 3 g Aluminum collapsible tube	₱63.00
69	Clotrimazole	1% Cream in 10 g Aluminum collapsible tube	₱118.25
70	Clotrimazole	1% Cream in 20 g Aluminum collapsible tube	₱80.75
71	Cloxacillin	500 mg (as sodium) capsule	₱7.75
72	Cloxacillin	250 mg/5 mL (as sodium) powder for solution in 60 mL	₱74.50
73	Colchicine	500 mcg tablet	₱3.25
74	Dapagliflozin	10 mg film-coated tablet	₱25.75
75	Diltiazem	60 mg (as hydrochloride) modified release capsule	₱15.75

MASTER COPY 10/3/26

No.	Molecule	Preparation	fixed fee
76	Diltiazem	120 mg (as hydrochloride) modified release capsule	₱96.50
77	Diltiazem	180 mg (as hydrochloride) modified release capsule	₱115.75
78	Diltiazem	60 mg (as hydrochloride) tablet	₱21.00
79	Diltiazem	120 mg (as hydrochloride) modified release tablet	₱96.50
80	Diltiazem	180 mg (as hydrochloride) modified release tablet	₱115.75
81	Diphenhydramine	25 mg (as hydrochloride) capsule	₱14.75
82	Diphenhydramine	50 mg (as hydrochloride) capsule	₱12.75
83	Diphenhydramine	12.5 mg/5 mL (as hydrochloride) syrup in 30 mL	₱77.25
84	Diphenhydramine	12.5 mg/ 5 mL (as hydrochloride) syrup in 60 mL	₱108.00
85	Doxycycline	100 mg (as hyclate) capsule	₱23.75
86	Ethambutol	100 mg (as Hydrochloride) tablet (pediatric)	₱4.25
87	Ethambutol	200 mg (as Hydrochloride) tablet	₱4.25
88	Ethambutol	400 mg (as Hydrochloride) tablet	₱ 5.00
89	Enalapril[a]	5 mg (as maleate) tablet	₱6.00
90	Enalapril[a]	20 mg (as maleate) tablet	₱11.00
91	Enalapril + Hydrochlorothiazide	20 mg + 12.5 mg tablet	₱16.00
92	Erythromycin	500 mg (as stearate) tablet	₱10.75
93	Erythromycin	200 mg/5 mL (as ethyl succinate) for suspension in 60 mL	₱318.50
94	Erythromycin	0.5% ophthalmic ointment in 3.5 g tube	₱167.50
95	Erythromycin	0.5% ophthalmic ointment in 5 g tube	₱153.50
96	Fenofibrate	200 mg capsule	₱15.75
97	Fenofibrate	160 mg tablet	₱27.25
98	Fluconazole	50 mg capsule	₱186.75
99	Fluconazole	150 mg capsule	₱375.00
100	Fluconazole	200 mg capsule	₱693.00
101	Fluticasone + Salmeterol[a]	50 mcg (as propionate) + 25 mcg (as xinafoate) x 120 actuations MDI with dose counter	₱429.25
102	Fluticasone + Salmeterol[a]	125 mcg (as propionate) + 25 mcg (as xinafoate) x 120 actuations MDI with dose counter	₱569.25
103	Fluticasone + Salmeterol[a]	250 mcg (as propionate) + 25 mcg (as xinafoate) x 120 actuations MDI with dose counter	₱737.00
104	Fluticasone + Salmeterol[a]	100 mcg (as propionate) + 50 mcg (as xinafoate) x 28 doses DPI with appropriate accompanying dispenser	₱1,084.50
105	Fluticasone + Salmeterol[a]	100 mcg (as propionate) + 50 mcg (as xinafoate) x 60 doses DPI with appropriate accompanying dispenser	₱1,084.50
106	Fluticasone + Salmeterol[a]	250 mcg (as propionate) + 50 mcg (as xinafoate) x 28 doses DPI with appropriate accompanying dispenser	₱1,500.75
107	Fluticasone + Salmeterol[a]	250 mcg (as propionate) + 50 mcg (as xinafoate) x 60 doses DPI with appropriate accompanying dispenser	₱1,156.25
108	Fluticasone + Salmeterol[a]	500 mcg (as propionate) + 50 mcg (as xinafoate) x 28 doses DPI with appropriate accompanying dispenser	₱798.50
109	Fluticasone + Salmeterol[a]	500 mcg (as propionate) + 50 mcg (as xinafoate) x 60 doses DPI with appropriate accompanying dispenser	₱1,981.75
110	Folic Acid + Iron Ferrous	60 mg (elemental iron) + 400 mcg capsule	₱8.75
111	Folic Acid + Iron Ferrous	60 mg (elemental iron) + 400 mcg tablet	₱8.75
112	Folic Acid + Iron Ferrous	60 mg (elemental iron) + 400 mcg film-coated tablet	₱8.75
113	Gabapentin	100 mg capsule	₱25.75
114	Gabapentin	300 mg capsule	₱32.50

MASTER COPY
Date: 10/13/16

No.	Molecule	Preparation	fixed fee
115	Gliclazide[a]	30 mg modified release tablet	₱6.75
116	Gliclazide[a]	60 mg modified release tablet	₱27.00
117	Gliclazide[a]	80 mg tablet	₱2.50
118	Hydrochlorothiazide[a]	12.5 mg tablet	₱3.50
119	Hydrochlorothiazide[a]	25 mg tablet	₱4.00
120	Ibuprofen	200 mg tablet	₱5.00
121	Ibuprofen	400 mg tablet	₱8.75
122	Ibuprofen	100 mg/5 mL syrup/suspension in 60 mL	₱67.75
123	Ibuprofen	200 mg/5 mL syrup/suspension in 60 mL	₱103.75
124	Ipratropium	250 mcg/mL (as bromide) respiratory solution in 2 mL unit dose (for nebulization)	₱29.75
125	Ipratropium + Salbutamol	500 mcg (as bromide anhydrous) + 2.5 mg (as base) respiratory solution in 2.5 mL unit dose (for nebulization)	₱45.25
126	Ipratropium + Salbutamol	20 mcg (as bromide) + 100 mcg x 200 doses x 10 mL MDI	₱1,083.00
127	Iron (Ferrous Salt)	Equivalent to 60 mg elemental iron tablet	₱1.25
128	Iron (Ferrous Salt)	Equivalent to 15 mg elemental iron per 0.6 mL solution (drops) in 15 mL	₱31.50
129	Iron (Ferrous Salt)	Equivalent to 15 mg elemental iron per 0.6 mL solution (drops) in 30 mL	₱252.00
130	Iron (Ferrous Salt)	Equivalent to 30 mg elemental iron per 5 mL solution (syrup) in 60 ml	₱259.00
131	Isoniazid + Rifampicin	50 mg isoniazid + 75 mg rifampicin dispersible fixed-dose combination tablet (pediatric)	₱ 7.25
132	Isoniazid + Rifampicin	75 mg isoniazid + 150 mg rifampicin tablet	₱ 8.25
133	Isoniazid + Rifampicin + Pyrazinamide	50 mg isoniazid + 75 mg rifampicin + 150 mg pyrazinamide dispersible fixed-dose combination tablets (pediatric)	₱ 8.75
134	Isoniazid + Rifampicin + Pyrazinamide + Ethambutol	75 mg isoniazid + 150 mg rifampicin + 400 mg pyrazinamide + 275 mg ethambutol tablet	₱ 9.75
135	Isosorbide Dinitrate	5 mg (as dinitrate) sublingual tablet	₱18.00
136	Isosorbide Dinitrate	10 mg (as dinitrate) tablet	₱15.75
137	Isosorbide Dinitrate	20 mg (as dinitrate) tablet	₱4.75
138	Isosorbide Dinitrate	20 mg (as dinitrate) modified release tablet	₱18.50
139	Isosorbide Mononitrate	40 mg (as 5-mononitrate) tablet	₱8.25
140	Isosorbide Mononitrate	30 mg (as 5-mononitrate) modified release capsule	₱14.50
141	Isosorbide Mononitrate	60 mg (as 5-mononitrate) modified release capsule	₱20.75
142	Isosorbide Mononitrate	30 mg (as 5-mononitrate) modified release tablet	₱17.00
143	Isosorbide Mononitrate	60 mg (as 5-mononitrate) modified release tablet	₱37.50
144	Ketoconazole	2% (20 mg/g) cream in 3.5 g aluminum collapsible tube	₱118.75
145	Ketoconazole	2% (20 mg/g) cream in 15 g aluminum collapsible tube	₱91.50
146	Ketoconazole	2% (20 mg/g) shampoo in 6 mL foil sachet	₱51.75
147	Ketoconazole	2% (20 mg/g) shampoo in 60 mL bottle	₱242.25
148	Ketoconazole	2% (20 mg/g) shampoo in 100 mL bottle	₱433.50
149	Loratadine	10 mg tablet	₱4.25
150	Loratadine	10 mg film-coated tablet	₱4.25
151	Loratadine	5 mg/5 mL syrup in 30 mL	₱208.50
152	Losartan[a]	50 mg (as potassium) tablet	₱9.00
153	Losartan[a]	100 mg (as potassium) tablet	₱12.00

MASTER COPY 10/13/26 DOH

No.	Molecule	Preparation	fixed fee
154	Losartan + Hydrochlorothiazide	50 mg + 12.5 mg tablet	₱9.50
155	Mebendazole	100 mg tablet	₱6.00
156	Mebendazole	100 mg capsule	₱6.00
157	Mebendazole	500 mg tablet	₱41.50
158	Mebendazole	500 mg chewable tablet	₱11.25
159	Mebendazole	50 mg/mL suspension in 10 mL	₱127.00
160	Mebendazole	100 mg/5 mL suspension in 30 mL	₱305.00
161	Mebendazole	100 mg/5 mL suspension in 60 mL	₱40.75
162	Mefenamic Acid	250 mg capsule	₱3.00
163	Mefenamic Acid	500 mg capsule	₱3.50
164	Mefenamic Acid	250 mg tablet	₱3.00
165	Mefenamic Acid	500 mg tablet	₱3.50
166	Metformin[a]	500 mg (as hydrochloride) film-coated tablet	₱4.75
167	Metformin[a]	500 mg (as hydrochloride) tablet	₱4.75
168	Metformin[a]	850 mg (as hydrochloride) tablet	₱5.25
169	Methyldopa	250 mg tablet	₱11.00
170	Metoprolol[a]	50 mg (as tartrate) tablet	₱2.25
171	Metoprolol[a]	100 mg (as tartrate) tablet	₱3.50
172	Metronidazole	250 mg tablet	₱11.00
173	Metronidazole	500 mg tablet	₱13.25
174	Metronidazole	125 mg/5 mL (as base) or 200 mg/mL (as benzoate) suspension in 60 mL	₱81.50
175	Montelukast	4 mg (as sodium) granules in Sachet	₱22.00
176	Montelukast	4 mg (as sodium) chewable tablet	₱20.50
177	Montelukast	5 mg (as sodium) chewable tablet	₱15.50
178	Montelukast	10 mg (as sodium) tablet	₱28.75
179	Naproxen	275 mg (as sodium) or 250 mg (base) tablet	₱7.00
180	Naproxen	550 mg (as sodium) or 200 mg (base) tablet	₱12.50
181	Nitrofurantoin[a]	50 mg (as macrocrystals) capsule	₱35.75
182	Nitrofurantoin[a]	100 mg (as macrocrystals) capsule	₱17.00
183	Omeprazole	20 mg capsule	₱19.00
184	Omeprazole	40 mg capsule	₱27.50
185	Oral Rehydration Salts (ORS 75-replacement)[a]	Composition (gram per L of water): Sodium chloride = 2.6 g Trisodium citrate dihydrate = 2.9 g Potassium chloride = 1.5 g Glucose anhydrous = 13.5 g Total weight = 20.5 g Composed of (mmol/L): Sodium = 75 Chloride = 65 Potassium = 20 Citrate = 10 Glucose anhydrous = 75 Total osmolarity = 245	₱12.00
186	Oseltamivir	75 mg (as phosphate) capsule	₱110.00
187	Paracetamol[a]	300 mg tablet	₱3.00
188	Paracetamol[a]	500 mg tablet	₱2.25

MASTER COPY
DC: Date: 10/13/26

No.	Molecule	Preparation	fixed fee
189	Paracetamol[a]	100 mg/mL drops (alcohol-free) in 15 mL	₱49.50
190	Paracetamol[a]	120 mg/5 mL (125 mg/5 mL) syrup (alcohol-free) in 30 ml	₱95.00
191	Paracetamol[a]	120 mg/5 mL (125 mg/5 mL) suspension (alcohol-free) in 30 ml	₱95.00
192	Paracetamol[a]	120 mg/5 mL (125 mg/5 mL) syrup (alcohol-free) in 60 mL	₱35.00
193	Paracetamol[a]	120 mg/5 mL (125 mg/5 mL) suspension (alcohol-free) in 60 mL	₱35.00
194	Paracetamol[a]	120 mg/5 mL (125 mg/5 mL) syrup (alcohol-free) in 120 ml	₱138.75
195	Paracetamol[a]	120 mg/5 mL (125 mg/5 mL) suspension (alcohol-free) in 120 ml	₱138.75
196	Paracetamol[a]	250 mg/5 mL syrup (alcohol-free) in 30 ml	₱77.75
197	Paracetamol[a]	250 mg/5 mL suspension (alcohol-free) in 30 ml	₱77.75
198	Paracetamol[a]	250 mg/5 mL syrup (alcohol-free) in 60 mL	₱52.50
199	Paracetamol[a]	250 mg/5 mL suspension (alcohol-free) in 60 mL	₱52.50
200	Paracetamol[a]	250 mg/5 mL syrup (alcohol-free) in 120 ml	₱255.00
201	Paracetamol[a]	250 mg/5 mL suspension (alcohol-free) in 120 ml	₱255.00
202	Paracetamol[a]	125 mg suppository	₱6.75
203	Paracetamol[a]	250 mg suppository	₱29.25
204	Prednisone[a]	5 mg tablet	₱1.75
205	Prednisone[a]	10 mg tablet	₱3.25
206	Prednisone[a]	20 mg tablet	₱6.50
207	Prednisone[a]	10 mg/5 mL suspension in 60 mL	₱134.25
208	Rosuvastatin	10 mg (as calcium) tablet	₱16.25
209	Rosuvastatin	20 mg (as calcium) tablet	₱23.25
210	Salbutamol[a]	2 mg/5 mL (as sulfate) syrup in 60 mL	₱60.00
211	Salbutamol[a]	1 mg/mL (as sulfate) respiratory solution in 2.5 mL unit dose (for nebulization)	₱18.00
212	Salbutamol[a]	2 mg/mL (as sulfate) respiratory solution in 2.5 mL unit dose (for nebulization)	₱32.00
213	Salbutamol[a]	200 mcg/dose (as sulfate) DPI with appropriate accompanying dispenser	₱7.00
214	Salbutamol[a]	100 mcg/dose (as sulfate) x 200 actuations MDI	₱195.50
215	Simvastatin[a]	20 mg tablet	₱6.50
216	Simvastatin[a]	40 mg tablet	₱10.00
217	Sulfamethoxazole + Trimethoprim (Co-trimoxazole)[a]	400 mg + 80 mg tablet	₱3.00
218	Sulfamethoxazole + Trimethoprim (Co-trimoxazole)[a]	800 mg + 160 mg tablet	₱9.50
219	Sulfamethoxazole + Trimethoprim (Co-trimoxazole)[a]	200 mg + 40 mg/5 mL suspension in 70 mL	₱56.00
220	Sulfamethoxazole + Trimethoprim (Co-trimoxazole)[a]	200 mg + 40 mg/5 mL suspension in 120 mL	₱53.25
221	Sulfamethoxazole + Trimethoprim (Co-trimoxazole)[a]	400 mg + 80 mg/5 mL suspension in 60 mL	₱139.00

MASTER COPY
Date: 10/13/26

No.	Molecule	Preparation	fixed fee
222	Tamsulosin	200 mcg (as hydrochloride) capsule	₱47.00
223	Tamsulosin	200 mcg orally disintegrating tablet	₱10.50
224	Tamsulosin	400 mcg prolonged release film coated tablet	₱30.50
225	Telmisartan	40 mg tablet	₱10.00
226	Telmisartan	80 mg tablet	₱13.75
227	Telmisartan + Hydrochlorothiazide	40 mg + 12.5 mg tablet	₱11.75
228	Tiotropium	18 mcg/dose (as bromide) DPI with appropriate accompanying dispenser	₱52.50
229	Tobramycin	0.3% ophthalmic drop solution in 5 mL bottle	₱345.00
230	Tobramycin	0.3% ophthalmic ointment in 3.5 g tube	₱519.50
231	Tobramycin + Dexamethasone	0.3% + 0.1% ophthalmic drop suspension in 5 mL bottle	₱164.50
232	Tobramycin + Dexamethasone	0.3% + 0.1% ophthalmic ointment in 3.5 g tube	₱491.00
233	Valsartan	80 mg tablet	₱14.50
234	Valsartan	160 mg tablet	₱17.50
235	Valsartan	80 mg film-coated tablet	₱14.50
236	Valsartan	160 mg film-coated tablet	₱17.50
237	Valsartan + Hydrochlorothiazide	80 mg + 12.5 mg tablet	₱16.75
238	Vitex Negundo (Lagundi)	300 mg tablet	₱4.00
239	Vitex Negundo (Lagundi)	600 mg tablet	₱5.25
240	Vitex Negundo (Lagundi)	300 mg/5 mL syrup in 60 mL	₱79.00
241	Vitex Negundo (Lagundi)	300 mg/5 mL syrup in 120 mL	₱128.00
242	Vitex Negundo (Lagundi)	600 mg/5 mL syrup in 60 mL	₱97.50
243	Vitex Negundo (Lagundi)	600 mg/5 mL syrup in 120 mL	₱139.75
244	Zinc	Equivalent to 10 mg elemental zinc (as gluconate) chewable tablet	₱3.25
245	Zinc	Equivalent to 30 mg elemental zinc (as gluconate trihydrate) tablet	₱5.00
246	Zinc	Equivalent to 10 mg elemental zinc per mL (as sulfate monohydrate) drops in 15 mL	₱51.50
247	Zinc	Equivalent to 20 mg elemental zinc per 5 mL (as sulfate monohydrate) syrup in 60 mL	₱85.00
248	Zinc	70 mg/5 mL (equivalent to 10 mg elemental zinc) (as gluconate) syrup in 60 mL	₱93.00
249	Zinc	70 mg/5 mL (equivalent to 10 mg elemental zinc) (as gluconate) syrup in 120 mL	₱88.50

[a]21 drugs included in PhilHealth YAKAP (formerly Konsulta); covered under PhilHealth YAKAP for CY 2026

MASTER COPY
DC: Date: 10/13/26

Annex B: Certification of Availability of GAMOT Template

PhilHealth
Your Partner in Health

[Name of Pharmacy]
[Address of Pharmacy]
[Contact Number of Pharmacy]

This certifies that **[Name of Drug Dispensing Facility]** currently stocks the molecules and preparations listed below. Furthermore, **[Name of Drug Dispensing Facility]** commits to maintaining the availability of these specific molecules and preparations at all times, upon engagement with PhilHealth.

No.	Molecule	Preparation	Available (Yes or No)	Brand(s)
1	Albendazole	400 mg chewable tablet		
2	Aluminum Hydroxide + Magnesium Hydroxide	200 mg + 100 mg tablet		
3	Aluminum Hydroxide + Magnesium Hydroxide	225 mg + 200 mg/5 mL suspension in 60 mL		
4	Aluminum Hydroxide + Magnesium Hydroxide	225 mg + 200 mg/5 mL suspension in 120 mL		
5	Amlodipine	5 mg (as besilate/camsylate) tablet		
6	Amlodipine	10 mg (as besilate/camsylate) tablet		
7	Amoxicillin	250 mg (as trihydrate) capsule		
8	Amoxicillin	500 mg (as trihydrate) capsule		
9	Amoxicillin	100 mg/mL (as trihydrate) granules/powder for drops in 15 mL		
10	Amoxicillin	250 mg/5 mL (as trihydrate) granules/powder for suspension in 60 mL		
11	Amoxicillin + Clavulanic acid (Co-Amoxiclav)	500 mg (as trihydrate) + 125 mg (as potassium clavulanate) tablet		
12	Amoxicillin + Clavulanic acid (Co-Amoxiclav)	875 mg (as trihydrate) + 125 mg (as potassium clavulanate) tablet		
13	Amoxicillin + Clavulanic acid (Co-Amoxiclav)	200 mg (as trihydrate) + 28.5 mg (as potassium clavulanate) per 5 mL granules/powder for suspension in 70 mL		
14	Amoxicillin + Clavulanic acid (Co-Amoxiclav)	400 mg (as Trihydrate) + 57 mg (as Potassium clavulanate) per 5 mL granules/powder for suspension in 70 mL		
15	Amoxicillin + Clavulanic acid (Co-Amoxiclav)	600 mg (as Trihydrate) + 42.9 mg (as Potassium clavulanate) per 5 mL granules/powder for suspension in 70 mL		
16	Aspirin	80 mg tablet		
17	Aspirin	100 mg tablet		
18	Atenolol	50 mg tablet		
19	Atenolol	100 mg tablet		
20	Atorvastatin	10 mg (as calcium) tablet		
21	Atorvastatin	20 mg (as calcium) tablet		
22	Atorvastatin	40 mg (as calcium) tablet		
23	Atorvastatin	80 mg (as calcium) tablet		
24	Azithromycin	250 mg (as base/dihydrate) capsule		

MASTER COPY
Date: 10/13/26
DC:

Annex B: Certification of Availability of GAMOT Template

No.	Molecule	Preparation	Available (Yes or No)	Brand(s)
25	Azithromycin	250 mg (as base/dihydrate/ monohydrate) tablet		
26	Azithromycin	500 mg (as base/dihydrate/ monohydrate) tablet		
27	Azithromycin	200 mg/5 mL (as base/dihydrate/ monohydrate) powder for suspension in 15 mL		
28	Azithromycin	200 mg/5 mL (as base/dihydrate/ monohydrate) powder for suspension in 60 mL		
29	Budesonide + Formoterol	80 mcg + 4.5 mcg (as fumarate dihydrate) x 60 doses DPI with appropriate accompanying dispenser		
30	Budesonide + Formoterol	160 mcg + 4.5 mcg (as fumarate dihydrate) x 60 doses DPI with appropriate accompanying dispenser		
31	Budesonide + Formoterol	320 mcg + 9 mcg (as fumarate) x 60 doses DPI with appropriate accompanying dispenser		
32	Budesonide + Formoterol	80 mcg + 4.5 mcg (as fumarate dihydrate) x 120 doses MDI with appropriate accompanying dispenser		
33	Budesonide + Formoterol	160 mcg + 4.5 mcg (as fumarate dihydrate) x 120 doses MDI with appropriate accompanying dispenser		
34	Butamirate	50 mg (as citrate) modified release tablet		
35	Butamirate	7.5 mg/5 mL (as citrate) syrup in 120 mL		
36	Captopril	25 mg tablet		
37	Captopril	50 mg tablet		
38	Cefixime	200 mg capsule		
39	Cefixime	400 mg capsule		
40	Cefixime	20 mg/mL granules for suspension (drops) in 10 mL		
41	Cefixime	100 mg/5 mL granules for suspension in 60 mL		
42	Cefuroxime	500 mg (as axetil) tablet		
43	Cefuroxime	125 mg/5 mL (as axetil) granules for suspension in 70 mL		
44	Cefuroxime	250 mg/5 mL granules for suspension in (50 mL content) in 120 mL Bottle		
45	Celecoxib	100 mg capsule		
46	Celecoxib	200 mg capsule		
47	Celecoxib	400 mg capsule		
48	Cetirizine	10 mg (as dihydrochloride) tablet		
49	Cetirizine	2.5 mg/mL (as dihydrochloride) syrup (drops) in 10 mL		
50	Cetirizine	10 mg/mL (as dihydrochloride) drops in 10 ml		
51	Cetirizine	1 mg/mL (as dihydrochloride) solution in 30 mL		
52	Cetirizine	1 mg/mL (as dihydrochloride) solution in 60 mL		
53	Cetirizine	5 mg/5 mL (as dihydrochloride) syrup 30 mL		
54	Chlorphenamine	4 mg (as maleate) tablet		
55	Chlorphenamine	2.5 mg/5 mL (as maleate) syrup in 60 mL		
56	Ciprofloxacin	250 mg (as hydrochloride) tablet		
57	Ciprofloxacin	500 mg (as hydrochloride) tablet		
58	Clarithromycin	250 mg (as base) tablet		
59	Clarithromycin	500 mg (as base) tablet		

MASTER COPY
Date: 10/13/26
DG

Annex B: Certification of Availability of GAMOT Template

No.	Molecule	Preparation	Available (Yes or No)	Brand(s)
60	Clarithromycin	125 mg/5 mL granules/powder for suspension in 50 mL		
61	Clarithromycin	250 mg/5 mL granules/powder for suspension in 50 mL		
62	Clindamycin	150 mg (as hydrochloride) capsule		
63	Clindamycin	300 mg (as hydrochloride) capsule		
64	Clindamycin	75 mg/5 mL (as palmitate hydrochloride) granules for suspension in 60 mL		
65	Clonidine	75 mcg (as hydrochloride) tablet		
66	Clonidine	150 mcg (as hydrochloride) tablet		
67	Clopidogrel	75 mg tablet		
68	Clotrimazole	1% Cream in 3 g Aluminum collapsible tube		
69	Clotrimazole	1% Cream in 10 g Aluminum collapsible tube		
70	Clotrimazole	1% Cream in 20 g Aluminum collapsible tube		
71	Cloxacillin	500 mg (as sodium) capsule		
72	Cloxacillin	250 mg/5 mL (as sodium) powder for solution in 60 mL		
73	Colchicine	500 mcg tablet		
74	Dapagliflozin	10 mg film-coated tablet		
75	Diltiazem	60 mg (as hydrochloride) modified release capsule		
76	Diltiazem	120 mg (as hydrochloride) modified release capsule		
77	Diltiazem	180 mg (as hydrochloride) modified release capsule		
78	Diltiazem	60 mg (as hydrochloride) tablet		
79	Diltiazem	120 mg (as hydrochloride) modified release tablet		
80	Diltiazem	180 mg (as hydrochloride) modified release tablet		
81	Diphenhydramine	25 mg (as hydrochloride) capsule		
82	Diphenhydramine	50 mg (as hydrochloride) capsule		
83	Diphenhydramine	12.5 mg/mL (as hydrochloride) syrup in 30 mL		
84	Diphenhydramine	12.5 mg/ 5mL (as hydrochloride) syrup in 60 mL		
85	Doxycycline	100 mg (as hyclate) capsule		
86	Ethambutol	100 mg (as Hydrochloride) tablet (pediatric)		
87	Ethambutol	200 mg (as Hydrochloride) tablet		
88	Ethambutol	400 mg (as Hydrochloride) tablet		
89	Enalapril	5 mg (as maleate) tablet		
90	Enalapril	20 mg (as maleate) tablet		
91	Enalapril + Hydrochlorothiazide	20 mg + 12.5 mg tablet		
92	Erythromycin	500 mg (as stearate) tablet		
93	Erythromycin	200 mg/5 mL (as ethyl succinate) for suspension in 60 mL		
94	Erythromycin	0.5% ophthalmic ointment in 3.5 g tube		
95	Erythromycin	0.5% Ophthalmic ointment in 5 g Tube		
96	Fenofibrate	200 mg capsule		
97	Fenofibrate	160 mg tablet		
98	Fluconazole	50 mg capsule		

MASTER COPY
Date: 10/13/26
DC.

No.	Molecule	Preparation	Available (Yes or No)	Brand(s)
99	Fluconazole	150 mg capsule		
100	Fluconazole	200 mg capsule		
101	Fluticasone + Salmeterol	50 mcg (as propionate) + 25 mcg (as xinafoate) x 120 actuations MDI with dose counter		
102	Fluticasone + Salmeterol	125 mcg (as propionate) + 25 mcg (as xinafoate) x 120 actuations MDI with dose counter		
103	Fluticasone + Salmeterol	250 mcg (as propionate) + 25 mcg (as xinafoate) x 120 actuations MDI with dose counter		
104	Fluticasone + Salmeterol	100 mcg (as propionate) + 50 mcg (as xinafoate) x 28 doses DPI with appropriate accompanying dispenser		
105	Fluticasone + Salmeterol	100 mcg (as propionate) + 50 mcg (as xinafoate) x 60 doses DPI with appropriate accompanying dispenser		
106	Fluticasone + Salmeterol	250 mcg (as propionate) + 50 mcg (as xinafoate) x 28 doses DPI with appropriate accompanying dispenser		
107	Fluticasone + Salmeterol	250 mcg (as propionate) + 50 mcg (as xinafoate) x 60 doses DPI with appropriate accompanying dispenser		
108	Fluticasone + Salmeterol	500 mcg (as propionate) + 50 mcg (as xinafoate) x 28 doses DPI with appropriate accompanying dispenser		
109	Fluticasone + Salmeterol	500 mcg (as propionate) + 50 mcg (as xinafoate) x 60 doses DPI with appropriate accompanying dispenser		
110	Folic Acid + Iron Ferrous	60 mg (elemental iron) + 400 mcg capsule		
111	Folic Acid + Iron Ferrous	60 mg (elemental iron) + 400 mcg tablet		
112	Folic Acid + Iron Ferrous	60 mg (elemental iron) + 400 mcg film-coated tablet		
113	Gabapentin	100 mg capsule		
114	Gabapentin	300 mg capsule		
115	Gliclazide	30 mg modified release tablet		
116	Gliclazide	60 mg modified release tablet		
117	Gliclazide	80 mg tablet		
118	Hydrochlorothiazide	12.5 mg tablet		
119	Hydrochlorothiazide	25 mg tablet		
120	Ibuprofen	200 mg tablet		
121	Ibuprofen	400 mg tablet		
122	Ibuprofen	100 mg/5 mL syrup/suspension in 60 mL		
123	Ibuprofen	200 mg/5 mL syrup/suspension in 60 mL		
124	Ipratropium	250 mcg/mL (as bromide) respiratory solution in 2 mL unit dose (for nebulization)		
125	Ipratropium + Salbutamol	500 mcg (as bromide anhydrous) + 2.5 mg (as base) respiratory solution in 2.5 mL unit dose (for nebulization)		
126	Ipratropium + Salbutamol	20 mcg (as bromide) + 100 mcg x 200 doses x 10 mL MDI		
127	Iron (Ferrous Salt)	Equivalent to 60 mg elemental iron tablet		
128	Iron (Ferrous Salt)	Equivalent to 15 mg elemental iron per 0.6 mL solution (drops) in 15 mL		
129	Iron (Ferrous Salt)	Equivalent to 15 mg elemental iron per 0.6 mL solution (drops) in 30 mL		
130	Iron (Ferrous Salt)	Equivalent to 30 mg elemental iron per 5 mL solution (syrup) in 60 ml		

MASTER COPY
Date: 10/13/26
DS:

Annex B: Certification of Availability of GAMOT Template

No.	Molecule	Preparation	Available (Yes or No)	Brand(s)
131	Isoniazid + Rifampicin	50 mg isoniazid + 75 mg rifampicin dispersible fixed-dose combination tablet (pediatric)		
132	Isoniazid + Rifampicin	75 mg isoniazid + 150 mg rifampicin tablet		
133	Isoniazid + Rifampicin + Pyrazinamide	50 mg isoniazid + 75 mg rifampicin + 150 mg pyrazinamide dispersible fixed-dose combination tablets (pediatric)		
134	Isoniazid + Rifampicin + Pyrazinamide + Ethambutol	75 mg isoniazid + 150 mg rifampicin + 400 mg pyrazinamide + 275 mg ethambutol tablet		
135	Isosorbide Dinitrate	5 mg (as dinitrate) sublingual tablet		
136	Isosorbide Dinitrate	10 mg (as dinitrate) tablet		
137	Isosorbide Dinitrate	20 mg (as dinitrate) tablet		
138	Isosorbide Dinitrate	20 mg (as dinitrate) modified release tablet		
139	Isosorbide Mononitrate	40 mg (as 5-mononitrate) tablet		
140	Isosorbide Mononitrate	30 mg (as 5-mononitrate) modified release capsule		
141	Isosorbide Mononitrate	60 mg (as 5-mononitrate) modified release capsule		
142	Isosorbide Mononitrate	30 mg (as 5-mononitrate) modified release tablet		
143	Isosorbide Mononitrate	60 mg (as 5-mononitrate) modified release tablet		
144	Ketoconazole	2% (20 mg/g) cream in 3.5 g aluminum collapsible tube		
145	Ketoconazole	2% (20 mg/g) cream in 15 g aluminum collapsible tube		
146	Ketoconazole	2% (20 mg/g) shampoo in 6 mL foil sachet		
147	Ketoconazole	2% (20 mg/g) shampoo in 60 mL bottle		
148	Ketoconazole	2% (20 mg/g) shampoo in 100 mL bottle		
149	Loratadine	10 mg tablet		
150	Loratadine	10 mg film-coated tablet		
151	Loratadine	5 mg/5 mL syrup in 30 mL		
152	Losartan	50 mg (as potassium) tablet		
153	Losartan	100 mg (as potassium) tablet		
154	Losartan + Hydrochlorothiazide	50 mg + 12.5 mg tablet		
155	Mebendazole	100 mg tablet		
156	Mebendazole	100 mg capsule		
157	Mebendazole	500 mg tablet		
158	Mebendazole	500 mg chewable tablet		
159	Mebendazole	50 mg/mL suspension in 10 mL		
160	Mebendazole	100 mg/5 mL suspension in 30 mL		
161	Mebendazole	100 mg/5 mL suspension in 60 mL		
162	Mefenamic Acid	250 mg capsule		
163	Mefenamic Acid	500 mg capsule		
164	Mefenamic Acid	250 mg tablet		
165	Mefenamic Acid	500 mg tablet		
166	Metformin	500 mg (as hydrochloride) film-coated tablet		
167	Metformin	500 mg (as hydrochloride) tablet		
168	Metformin	850 mg (as hydrochloride) tablet		

MASTER COPY 10/13/20 DC

No.	Molecule	Preparation	Available (Yes or No)	Brand(s)
169	Methyldopa	250 mg tablet		
170	Metoprolol	50 mg (as tartrate) tablet		
171	Metoprolol	100 mg (as tartrate) tablet		
172	Metronidazole	250 mg tablet		
173	Metronidazole	500 mg tablet		
174	Metronidazole	125 mg/5 mL (as base) or 200 mg/mL (as benzoate) suspension in 60 mL		
175	Montelukast	4 mg (as sodium) granules in Sachet		
176	Montelukast	4 mg (as sodium) chewable tablet		
177	Montelukast	5 mg (as sodium) chewable tablet		
178	Montelukast	10 mg (as sodium) tablet		
179	Naproxen	275 mg (as sodium) or 250 mg (base) tablet		
180	Naproxen	550 mg (as sodium) or 200 mg (base) tablet		
181	Nitrofurantoin	50 mg (as macrocrystals) capsule		
182	Nitrofurantoin	100 mg (as macrocrystals) capsule		
183	Omeprazole	20 mg capsule		
184	Omeprazole	40 mg capsule		
185	Oral Rehydration Salts (ORS 75-replacement)	Composition (gram per L of water): Sodium chloride = 2.6 g Trisodium citrate dihydrate = 2.9 g Potassium chloride = 1.5 g Glucose anhydrous = 13.5 g Total weight = 20.5 g Composed of (mmol/L): Sodium = 75 Chloride = 65 Potassium = 20 Citrate = 10 Glucose anhydrous = 75 Total osmolarity = 245		
186	Oseltamivir	75 mg (as phosphate) capsule		
187	Paracetamol	300 mg tablet		
188	Paracetamol	500 mg tablet		
189	Paracetamol	100 mg/mL drops (alcohol-free) in 15 mL		
190	Paracetamol	120 mg/5 mL (125 mg/5 mL) syrup (alcohol-free) in 30 ml		
191	Paracetamol	120 mg/5 mL (125 mg/5 mL) suspension (alcohol-free) in 30 ml		
192	Paracetamol	120 mg/5 mL (125 mg/5 mL) syrup (alcohol-free) in 60 mL		
193	Paracetamol	120 mg/5 mL (125 mg/5 mL) suspension (alcohol-free) in 60 mL		
194	Paracetamol	120 mg/5 mL (125 mg/5 mL) syrup (alcohol-free) in 120 ml		
195	Paracetamol	120 mg/5 mL (125 mg/5 mL) suspension (alcohol-free) in 120 ml		
196	Paracetamol	250 mg/5 mL syrup (alcohol-free) in 30 ml		
197	Paracetamol	250 mg/5 mL suspension (alcohol-free) in 30 ml		
198	Paracetamol	250 mg/5 mL syrup (alcohol-free) in 60 mL		
199	Paracetamol	250 mg/5 mL suspension (alcohol-free) in 60 mL		
200	Paracetamol	250 mg/5 mL syrup (alcohol-free) in 120 ml		
201	Paracetamol	250 mg/5 mL suspension (alcohol-free) in 120 ml		

MASTER COPY
Date: 9/13/20
DOH

Annex B: Certification of Availability of GAMOT Template

No.	Molecule	Preparation	Available (Yes or No)	Brand(s)
202	Paracetamol	125 mg suppository		
203	Paracetamol	250 mg suppository		
204	Prednisone	5 mg tablet		
205	Prednisone	10 mg tablet		
206	Prednisone	20 mg tablet		
207	Prednisone	10 mg/5 mL suspension in 60 mL		
208	Rosuvastatin	10 mg (as calcium) tablet		
209	Rosuvastatin	20 mg (as calcium) tablet		
210	Salbutamol	2 mg/5 mL (as sulfate) syrup in 60 mL		
211	Salbutamol	1 mg/mL (as sulfate) respiratory solution in 2.5 mL unit dose (for nebulization)		
212	Salbutamol	2 mg/mL (as sulfate) respiratory solution in 2.5 mL unit dose (for nebulization)		
213	Salbutamol	200 mcg/dose (as sulfate) DPI with appropriate accompanying dispenser		
214	Salbutamol	100 mcg/dose (as sulfate) x 200 actuations MDI		
215	Simvastatin	20 mg tablet		
216	Simvastatin	40 mg tablet		
217	Sulfamethoxazole + Trimethoprim (Co-trimoxazole)	400 mg + 80 mg tablet		
218	Sulfamethoxazole + Trimethoprim (Co-trimoxazole)	800 mg + 160 mg tablet		
219	Sulfamethoxazole + Trimethoprim (Co-trimoxazole)	200 mg + 40 mg/5 mL suspension in 70 mL		
220	Sulfamethoxazole + Trimethoprim (Co-trimoxazole)	200 mg + 40 mg/5 mL suspension in 120 mL		
221	Sulfamethoxazole + Trimethoprim (Co-trimoxazole)	400 mg + 80 mg/5 mL suspension in 60 mL		
222	Tamsulosin	200 mcg (as hydrochloride) capsule		
223	Tamsulosin	200 mcg orally disintegrating tablet		
224	Tamsulosin	400 mcg prolonged release film coated tablet		
225	Telmisartan	40 mg tablet		
226	Telmisartan	80 mg tablet		
227	Telmisartan + Hydrochlorothiazide	40 mg + 12.5 mg tablet		
228	Tiotropium	18 mcg/dose (as bromide) DPI with appropriate accompanying dispenser		
229	Tobramycin	0.3% ophthalmic drop solution in 5 mL bottle		
230	Tobramycin	0.3% ophthalmic ointment in 3.5 g tube		
231	Tobramycin + Dexamethasone	0.3% + 0.1% ophthalmic drop suspension in 5 mL bottle		
232	Tobramycin + Dexamethasone	0.3% + 0.1% ophthalmic ointment in 3.5 g tube		
233	Valsartan	80 mg tablet		
234	Valsartan	160 mg tablet		
235	Valsartan	80 mg film-coated tablet		
236	Valsartan	160 mg film-coated tablet		
237	Valsartan + Hydrochlorothiazide	80 mg + 12.5 mg tablet		

MASTER COPY
Date: 10/13/26
DC:

Annex B: Certification of Availability of GAMOT Template

No.	Molecule	Preparation	Available (Yes or No)	Brand(s)
238	Vitex Negundo (Lagundi)	300 mg tablet		
239	Vitex Negundo (Lagundi)	600 mg tablet		
240	Vitex Negundo (Lagundi)	300 mg/5 mL syrup in 60 mL		
241	Vitex Negundo (Lagundi)	300 mg/5 mL syrup in 120 mL		
242	Vitex Negundo (Lagundi)	600 mg/5 mL syrup in 60 mL		
243	Vitex Negundo (Lagundi)	600 mg/5 mL syrup in 120 mL		
244	Zinc	Equivalent to 10 mg elemental zinc (as gluconate) chewable tablet		
245	Zinc	Equivalent to 30 mg elemental zinc (as gluconate trihydrate) tablet		
246	Zinc	Equivalent to 10 mg elemental zinc per mL (as sulfate monohydrate) drops in 15 mL		
247	Zinc	Equivalent to 20 mg elemental zinc per 5 mL (as sulfate monohydrate) syrup in 60 mL		
248	Zinc	70 mg/5 mL (equivalent to 10 mg elemental zinc) (as gluconate) syrup in 60 mL		
249	Zinc	70 mg/5 mL (equivalent to 10 mg elemental zinc) (as gluconate) syrup in 120 mL		

This certificate is being issued to PhilHealth as part of the requirements for accreditation as a GAMOT Facility.

_____

(Name and Signature of the Pharmacy Head / Representative)

Date: _____

MASTER COPY
DC: Date: 9/13/26

Annex C: PhilHealth GAMOT First-Line Anti-TB Drugs Dispensing Limits

Molecule	Preparation and Form	Use Case	Dispensing Limit
Ethambutol	100 mg (as Hydrochloride) tablet (pediatric)	Medication for drug-susceptible tuberculosis (children < 25 kg)	30 days
	200 mg (as Hydrochloride) tablet	Medication for drug-susceptible tuberculosis (children < 25 kg)	30 days
	400 mg (as Hydrochloride) tablet	Medication for drug-susceptible tuberculosis (children < 25 kg)	30 days
Isoniazid + Rifampicin	50 mg isoniazid + 75 mg rifampicin dispersible fixed-dose combination tablet (pediatric)	Medication for drug-susceptible tuberculosis (children < 25 kg)	30 days
	75 mg isoniazid + 150 mg rifampicin tablet	Medication for drug-susceptible tuberculosis (children ≥ 25 kg and adults)	30 days
Isoniazid + Rifampicin + Pyrazinamide	50 mg isoniazid + 75 mg rifampicin + 150 mg pyrazinamide dispersible fixed-dose combination tablets (pediatric)	Medication for drug-susceptible tuberculosis (children < 25 kg)	30 days
Isoniazid + Rifampicin + Pyrazinamide + Ethambutol	75 mg isoniazid + 150 mg rifampicin + 400 mg pyrazinamide + 275 mg ethambutol tablet	Medication for drug-susceptible tuberculosis (children ≥ 25 kg and adults)	30 days

Source: Department of Health National Tuberculosis Control Program Manual of Procedures 6th edition.

MASTER COPY
DC: Date: 10/13/22